These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15464913)

  • 61. Vaccines to treat cancer--an old approach whose time has arrived.
    Hellstrom KE; Hellstrom I
    J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Advances in the development of a therapeutic cancer vaccine.
    Avigan D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S2-6. PubMed ID: 16280106
    [No Abstract]   [Full Text] [Related]  

  • 63. Cancer vaccines: pessimism in check.
    Mocellin S; Mandruzzato S; Bronte V; Marincola FM
    Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242
    [No Abstract]   [Full Text] [Related]  

  • 64. Immunotherapy of prostate cancer.
    Doehn C
    Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
    [No Abstract]   [Full Text] [Related]  

  • 65. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
    Lévy F; Colombetti S
    Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Dendritic cell-based cancer vaccine].
    Burgdorf SK; Claësson MH; Rosenberg J
    Ugeskr Laeger; 2006 Apr; 168(14):1420-3. PubMed ID: 16584669
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Development of personalized peptide vaccines for advanced cancer patients].
    Yamada A
    Rinsho Ketsueki; 2005 Jun; 46(6):433-8. PubMed ID: 16447725
    [No Abstract]   [Full Text] [Related]  

  • 69. Therapeutic immunization against cancer antigens using genetically engineered cells.
    Sjögren HO
    Immunotechnology; 1997 Oct; 3(3):161-72. PubMed ID: 9358269
    [No Abstract]   [Full Text] [Related]  

  • 70. [Current status and future perspective of peptide vaccine for biliary tract cancer].
    Aruga A
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():823-6. PubMed ID: 25857143
    [No Abstract]   [Full Text] [Related]  

  • 71. Cancer vaccines: are we there yet?
    Hanna MG
    Hum Vaccin Immunother; 2012 Aug; 8(8):1161-5. PubMed ID: 22854657
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vaccine therapies for pediatric malignancies.
    Rousseau RF; Brenner MK
    Cancer J; 2005; 11(4):331-9. PubMed ID: 16197723
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Peptide vaccine for leukemia.
    Cancer Biol Ther; 2004 Dec; 3(12):1197. PubMed ID: 15864853
    [No Abstract]   [Full Text] [Related]  

  • 74. Somatic cell engineering and the immunotherapy of leukemias and lymphomas.
    Brentjens RJ; Sadelain M
    Adv Pharmacol; 2004; 51():347-70. PubMed ID: 15464917
    [No Abstract]   [Full Text] [Related]  

  • 75. A viral strategy to ambush tumors.
    Alvarez-Breckenridge C; Chiocca EA
    Nat Med; 2011 Jul; 17(7):784-5. PubMed ID: 21738155
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Immunotherapy of acute leukemia (author's transl)].
    Ohno R; Kato Y
    Rinsho Ketsueki; 1980 Sep; 21(9):1324-7. PubMed ID: 6450292
    [No Abstract]   [Full Text] [Related]  

  • 77. Chaperoning tumour antigens into the immune system.
    Featherstone C
    Lancet; 1996 Nov; 348(9039):1438. PubMed ID: 8965591
    [No Abstract]   [Full Text] [Related]  

  • 78. Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.
    O'Meara MM; Disis ML
    OMICS; 2011 Sep; 15(9):579-88. PubMed ID: 21732821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies.
    Migliorini D; Dietrich PY; Walker PR
    Immunotherapy; 2013 Nov; 5(11):1147-50. PubMed ID: 24188666
    [No Abstract]   [Full Text] [Related]  

  • 80. [Immunotherapy for head and neck cancer].
    Chikamatsu K
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):802-5. PubMed ID: 26298887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.